Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
Clinical trial NCT05633979 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05633979
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-09
- Primary completion
- 2030-12-31
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.